{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:14Z","timestamp":1792791494936,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ymthe.2025.06.028","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:37:00Z","timestamp":1749926220000},"page":"4848-4857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gene therapy with covalently closed-end AAV vector for spinal muscular atrophy"],"prefix":"10.1016","volume":"33","author":[{"given":"Haolin","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciliu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaole","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zou","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-980X","authenticated-orcid":false,"given":"Weidong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-6962","authenticated-orcid":false,"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.06.028_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"TACG"},{"key":"10.1016\/j.ymthe.2025.06.028_bib2","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy","volume":"55","author":"Govoni","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.06.028_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.06.028_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.06.028_bib5","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.06.028_bib6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.06.028_bib7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","article-title":"Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy","volume":"36","author":"Blair","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ymthe.2025.06.028_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec \u2013A Single Centre Experience","volume":"8","author":"Friese","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.06.028_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jpc.16340","article-title":"Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis","volume":"59","author":"Yang","year":"2023","journal-title":"J. Paediatr. Child Health"},{"issue":"supplement_2","key":"10.1016\/j.ymthe.2025.06.028_bib10","article-title":"FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA) (P7-9.009)","volume":"100","author":"Darras","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.06.028_bib11","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1017\/cjn.2023.88","article-title":"C.2 SUNFISH parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)","volume":"50","author":"Mah","year":"2023","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.ymthe.2025.06.028_bib12","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/hmg\/ddae052","article-title":"Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy","volume":"33","author":"Ma","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.06.028_bib13","doi-asserted-by":"crossref","first-page":"121096","DOI":"10.1016\/j.jns.2023.121096","article-title":"Sunfish parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)","volume":"455","author":"Oskoui","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymthe.2025.06.028_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ymthe.2025.06.028_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ymthe.2025.06.028_bib16","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.ymthe.2025.06.028_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2025.06.028_bib18","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.3390\/jcm10235540","article-title":"Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I","volume":"10","author":"Mirea","year":"2021","journal-title":"JCM"},{"key":"10.1016\/j.ymthe.2025.06.028_bib19","doi-asserted-by":"crossref","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"Pane","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ymthe.2025.06.028_bib20","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/pharmaceutics15061764","article-title":"Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy","volume":"15","author":"Ren\u00e9","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.06.028_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D\u2019Silva","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2025.06.028_bib23","doi-asserted-by":"crossref","first-page":"101206","DOI":"10.1016\/j.omtm.2024.101206","article-title":"A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR","volume":"32","author":"Zhang","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.06.028_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther."},{"key":"10.1016\/j.ymthe.2025.06.028_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/biomedicines2010080","article-title":"Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment","volume":"2","author":"Wright","year":"2014","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2025.06.028_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/iep.12478","article-title":"Clinical applications of gene therapy for rare diseases: A review","volume":"104","author":"Papaioannou","year":"2023","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ymthe.2025.06.028_bib27","first-page":"27","article-title":"Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program. Pediatr","volume":"132","author":"Chand","year":"2022","journal-title":"Neurol"},{"key":"10.1016\/j.ymthe.2025.06.028_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/hum.2022.161","article-title":"Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis","volume":"34","author":"Pascual-Morena","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.06.028_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2021","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ymthe.2025.06.028_bib30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41434-023-00401-5","article-title":"Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings","volume":"30","author":"Chand","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.06.028_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.06.028_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.028_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.06.028_bib34","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.06.028_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","article-title":"Gene therapy for spinal muscular atrophy: the Qatari experience","volume":"28","author":"Ali","year":"2021","journal-title":"Gene Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:41Z","timestamp":1792788461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625004794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1525001625004794"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.028","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy with covalently closed-end AAV vector for spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}